TY - JOUR T1 - First-Line Therapy in Ovarian Cancer Trials JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 756 LP - 762 DO - 10.1097/IGC.0b013e31821ce75d VL - 21 IS - 4 AU - Tate Thigpen AU - Andreas duBois AU - Jessica McAlpine AU - Philip DiSaia AU - Keiichi Fujiwara AU - William Hoskins AU - Gunnar Kristensen AU - Robert Mannel AU - Maurie Markman AU - Jacobus Pfisterer AU - Michael Quinn AU - Nick Reed AU - Ann Marie Swart AU - Jonathan Berek AU - Nicoletta Colombo AU - Gilles Freyer AU - Dolores Gallardo AU - Marie Plante AU - Andres Poveda AU - Lawrence Rubinstein AU - Monica Bacon AU - Henry Kitchener AU - Gavin C.E. Stuart Y1 - 2011/04/01 UR - http://ijgc.bmj.com/content/21/4/756.abstract N2 - At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients.A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)?A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials?A3: Is the 2004 GCIG-recommended standard comparator arm still valid?A4: What is the role of modifying dose, schedule, and delivery of chemotherapy?A5: What role does surgery play today? ER -